Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-11-05
DOI
10.3389/fimmu.2018.02551
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
- (2018) Cindy Varga et al. BRITISH JOURNAL OF HAEMATOLOGY
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival
- (2018) Ingemar Turesson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
- (2018) Ahmed T. Kurdi et al. MOLECULAR CANCER THERAPEUTICS
- Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or Exosome-Mediated IL15 Trans -Presentation
- (2018) Cristiana Borrelli et al. Cancer Immunology Research
- Daratumumab for the Treatment of Multiple Myeloma
- (2018) Torben Plesner et al. Frontiers in Immunology
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma
- (2017) Andrae Vandross SEMINARS IN ONCOLOGY
- Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
- (2017) Gianfranco Pittari et al. Frontiers in Immunology
- The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms
- (2017) Tatiana Pazina et al. OncoImmunology
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
- (2016) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
- (2016) Camille Guillerey et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
- (2016) P. Neri et al. CLINICAL CANCER RESEARCH
- Features of Memory-Like and PD-1+ Human NK Cell Subsets
- (2016) Mariella Della Chiesa et al. Frontiers in Immunology
- Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells
- (2016) Fabrizio Antonangeli et al. OncoImmunology
- Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
- (2015) K. Lagrue et al. BLOOD
- Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function
- (2015) Heinrich Schlums et al. IMMUNITY
- Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals
- (2015) Jaewon Lee et al. IMMUNITY
- bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression
- (2015) Sina Gordan et al. IMMUNOLOGICAL REVIEWS
- Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
- (2015) A Ray et al. LEUKEMIA
- Macrophages are critical effectors of antibody therapies for cancer
- (2015) Kipp Weiskopf et al. mAbs
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
- (2015) Cinzia Fionda et al. Oncotarget
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
- (2015) Zhigang Xie et al. Oncotarget
- Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
- (2014) Balaji Balasa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
- (2014) Luis-Alberto Pérez-Quintero et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Fine Specificity and Molecular Competition in SLAM Family Receptor Signalling
- (2014) Timothy J. Wilson et al. PLoS One
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
- (2013) Ashley Mentlik James et al. Frontiers in Immunology
- Role of the NK Cell-Activating Receptor CRACC in Periodontitis
- (2012) Benjamin Krämer et al. INFECTION AND IMMUNITY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Resolution Transcriptome of Human Macrophages
- (2012) Marc Beyer et al. PLoS One
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
- (2011) K. L. Wong et al. BLOOD
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
- (2010) I. H. Gabriel et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)
- (2010) Amanda K. Purdy et al. CANCER BIOLOGY & THERAPY
- Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells
- (2009) Mónica Bernal et al. HUMAN IMMUNOLOGY
- Importance and mechanism of ‘switch’ function of SAP family adapters
- (2009) André Veillette et al. IMMUNOLOGICAL REVIEWS
- M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
- (2009) M. Leidi et al. JOURNAL OF IMMUNOLOGY
- Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation
- (2009) C. Fionda et al. JOURNAL OF IMMUNOLOGY
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
- (2009) Mario-Ernesto Cruz-Munoz et al. NATURE IMMUNOLOGY
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
- (2008) S. Armeanu et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
- (2008) M. Jinushi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search